I fire fase- I kliniske studier var steady state eksponering af sorafenib ens hos patienter med mild til moderat nedsat nyrefunktion sammenlignet med eksponeringen af patienter med normal nyrefunktion.
In four Phase I clinical trials, steady state exposure to sorafenib was similar in patients with mild or moderate renal impairment compared to the exposures in patients with normal renal function.